Limited Use Status for Acamprosate and Naltrexone
Aug 30, 2018
Tagged alcohol use disorder, implications for practice, MOHLTC, pharmacotherapy
As of June 29, 2018, acamprosate and naltrexone can be prescribed under Limited Use Status in Ontario. Prescribers will no longer be required to obtain approval through the Exceptional Access Program. In addition to meeting the clinical criteria for alcohol use disorder (AUD), patients must have expressed a commitment to abstain from alcohol (for acamprosate) or a commitment to reduce or abstain from alcohol (for naltrexone). Patients are also required to confirm participation in counselling or psychosocial treatment.
The shift to Limited Use Status for these medications will now allow patients immediate access to evidence-based care.
New Limited Use codes
Acamprosate: LU 531
Naltrexone: LU 532
For more detailed requirements, please consult the MOHLTC Ontario Drug Benefit Formulary.
« Back to Blog